
Alzamend Neuro (ALZN) Stock Forecast & Price Target
Alzamend Neuro (ALZN) Analyst Ratings
Bulls say
Alzamend Neuro Inc. has reported positive top-line results from its clinical studies, indicating promising advancements in its therapeutic pipeline for treating neurodegenerative diseases and psychiatric disorders. The company's unique drug candidates, AL001 and AL002, utilize innovative technologies that have potential therapeutic benefits, particularly in combating Alzheimer's disease. With current valuations being considered attractive and anticipated key milestones poised to act as catalysts for growth, there is an optimistic outlook for the company’s future performance in the biopharmaceutical sector.
Bears say
Alzamend Neuro Inc reported a net loss of $2.7 million, equating to an earnings per share (EPS) of $(1.28), which was significantly worse than the estimates of $(0.69). The company faces numerous risks that could impede its financial performance, including balance sheet and liquidity concerns, potential failures in demonstrating the safety and efficacy of its product candidates during clinical trials, and challenges in obtaining regulatory approvals. Additionally, competitive pressures and changing macroeconomic factors may further undermine investor confidence and the overall investment climate for biotech stocks, contributing to the negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Alzamend Neuro and is not a guaranteed prediction by Public.com or investment advice.
Alzamend Neuro (ALZN) Analyst Forecast & Price Prediction
Start investing in Alzamend Neuro (ALZN)
Order type
Buy in
Order amount
Est. shares
0 shares